{"id":51032,"date":"2026-08-04T19:07:00","date_gmt":"2026-08-04T17:07:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=5d726fb6a3a5ebae626a5db1ba8817bf"},"modified":"2026-08-04T19:07:00","modified_gmt":"2026-08-04T17:07:00","slug":"phar-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-pharming-group-phar","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=51032","title":{"rendered":"PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)"},"content":{"rendered":"

Pharming Group missed Q2 2026 consensus revenue estimates and shares dropped 22% in a single session. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors who lost money.<\/i><\/p><\/a><\/a>

NEW YORK--(BUSINESS WIRE)--A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026 revenue of $90.2 million -- a 3% year-over-year decline against analyst consensus of roughly $419 million for the full year. If you lost money on PHAR, click here to submit your losses for review<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>

The miss came from the Company's legacy product. RUCONEST sales fell 10% year-over-year to $72.3 million. Although Joenja revenue rose 40% to $17.9 million -- the growth was not enough to offset the decline in RUCONEST. Diluted EPS came in at $0.002, down from $0.006 in the prior-year quarter.<\/p>

Alongside the results, Pharming reduced its full-year 2026 revenue outlook to $375 million to $395 million, from a prior range of $405 million to $425 million. The revised midpoint of $385 million was approximately $30 million below the previous midpoint and below analyst expectations.<\/p>

Shareholders who purchased PHAR and suffered a loss are encouraged to have their claim evaluated at no cost<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com<\/a> or by telephone at (212) 363-7500.<\/p>

ABOUT THE FIRM<\/b> -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.<\/p>

Frequently Asked Questions About the PHAR Investigation<\/p>

Q: How much did PHAR stock drop?<\/b> A: Shares fell approximately 22% on July 30, 2026 after the Company reported Q2 2026 revenue of $90.2 million and reduced its full-year 2026 revenue outlook to $375 million to $395 million. Investors who purchased shares and suffered losses may be eligible to seek recovery.<\/p>

Q: What is the PHAR securities investigation about?<\/b> A: A securities investigation is pending concerning Pharming Group (PHAR) regarding potentially materially false or misleading statements. Shares fell approximately 22% after the Company disclosed a Q2 revenue decline and a reduced full-year outlook, causing losses for shareholders.<\/p>

Q: Who is eligible to participate in the PHAR investigation?<\/b> A: Investors who purchased PHAR stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.<\/p>

Q: What do PHAR investors need to do right now?<\/b> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com<\/a> or (212) 363-7500.<\/p>

Q: What documents do I need to participate?<\/b> A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.<\/p>

Q: What if I already sold my PHAR shares -- can I still recover losses?<\/b> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought PHAR and sold at a loss may still participate in the investigation.<\/p>

Q: What does it cost me to participate?<\/b> A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.<\/p>

Q: What if I live outside the United States?<\/b> A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.<\/p>

Attorney Advertising. Prior results do not guarantee similar outcomes.<\/p> Contacts<\/b>

Levi & Korsinsky, LLPJoseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 27th FloorNew York, NY 10004jlevi@levikorsinsky.com<\/a>Tel: (212) 363-7500Fax: (212) 363-7171<\/p>","protected":false},"excerpt":{"rendered":"

Pharming Group missed Q2 2026 consensus revenue estimates and shares dropped 22% in a single session. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors who lost money.NEW YORK–(BUSINESS WIRE)–A 22% …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-51032","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51032"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51032\/revisions"}],"predecessor-version":[{"id":51033,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/51032\/revisions\/51033"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}